Amgen (AMGN) EBITDA (2009 - 2026)

Amgen's EBITDA history runs 18 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• In Q1 2026, EBITDA rose 126.32% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $10.6 billion (up 41.95% YoY), while the FY2025 annual figure was $9.1 billion, up 25.1% from the prior year.
• EBITDA was $2.7 billion for Q1 2026 at Amgen, down from $2.7 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.7 billion in Q4 2025 to a low of $991.0 million in Q1 2024.
• Historically, EBITDA has averaged $2.1 billion across 5 years, with a median of $2.2 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: EBITDA jumped 162.8% in 2022, then tumbled 48.41% in 2024.
• A 5-year view of EBITDA shows it stood at $2.2 billion in 2022, then sank by 43.0% to $1.3 billion in 2023, then soared by 81.83% to $2.3 billion in 2024, then rose by 17.7% to $2.7 billion in 2025, then retreated by 1.99% to $2.7 billion in 2026.
• The last three EBITDA figures came in at $2.7 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.